Neuphoria Therapeutics Inc. (NEUP) Institutional Ownership

Ownership Summary

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) showed up in the 13F filings of 21 institutional investors as of December 2025.

• Collectively, these holders controlled 33.0% of Neuphoria Therapeutics's outstanding shares in December 2025, up from 8.9% in September 2025.
• They increased total shares held in Neuphoria Therapeutics by 883.52% from the prior quarter, while the number of investors in NEUP increased 133.33% year over year.
• During the quarter, 17 of these 21 funds increased positions in NEUP, 2 reduced exposure, and 2 held steady.
• The aggregate institutional position in Neuphoria Therapeutics amounted to 1.5Mn shares as of December 2025, up by 1.34Mn shares quarter on quarter, and up 1.42Mn shares year over year.
• Lynx1 Capital Management LP holds the largest position in NEUP at 875.33K shares as of December 31, 2025, or 19.3% of shares outstanding.
• The most significant purchases of NEUP for the quarter ending December 2025 came from BALYASNY ASSET MANAGEMENT L.P. (142.18K), Squadron Capital Management LLC (76.73K), GEODE CAPITAL MANAGEMENT, LLC (34.7K), AdvisorShares Investments LLC (21.17K), CITADEL ADVISORS LLC (19.33K).
• Top sellers of NEUP stock for the quarter ending December 2025 included ADAR1 Capital Management, LLC (30.0K), Shay Capital LLC (18.05K).
• Per Business Quant, the top 10 investors in NEUP for the quarter ending December 2025 include Lynx1 Capital Management LP (875.33K), AdvisorShares Investments LLC (155.37K), Shay Capital LLC (151.01K), BALYASNY ASSET MANAGEMENT L.P. (142.18K), Squadron Capital Management LLC (76.73K), GEODE CAPITAL MANAGEMENT, LLC (52.01K), Ikarian Capital, LLC (47.44K), ADAR1 Capital Management, LLC (30.0K), FNY Investment Advisers, LLC (26.5K), CITADEL ADVISORS LLC (19.33K).